- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Accelerate Product Innovation & Availability
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
You are here
Trial Search
| Trial Name | Prevention Option | Phase | Start Date | Sponsors | Countries | Population | Candidate(s) | Status |
|---|---|---|---|---|---|---|---|---|
| IAVI G002 | HIV Vaccine | I | August 2021 | International AIDS Vaccine Initiative; ModernaTX, Inc.; The University of Texas at San Antonio; George Washington University; Fred Hutchinson Cancer Research Center; Emory University | Men, Women | Ongoing | ||
| Impower-024 | PrEP | III | March 2021 | Merck Sharp & Dohme Corp. | Men, MSM, Transgender women | Islatravir (MK-8591) | Ongoing | |
| Impower-022 | PrEP | III | February 2021 | Merck Sharp & Dohme Corp. | United States of America, South Africa | Women | Islatravir (MK-8591), TDF/FTC (Truvada) | Ongoing |
| SSPN formulations of novel emtricitabine | PrEP | Pre-clinical | emtricitabine | |||||
| Transdermal Delivery System for Tenofovir Alafenamide | PrEP | Pre-clinical | Eastern Virginia Medical School, CONRAD, Corporation of Mercer University, USAID/PEPFAR | F/TAF | Stopped Early | |||
| CAPRISA 018 | PrEP | I | January 2017 | Centre for the Aids Programme of Research in South Africa; Stichting Amsterdam Institute for Global Health and Development; Université Jean Monnet, Saint-Etienne | Women | tenofovir | Ongoing | |
| 90-day Pod-type Etonogestrel/Ethinyl Estradiol/QGriffithsin (QGRFT) Intravaginal Ring [EEQ IVR] | Microbicides | Pre-clinical | April 2020 | NIAID | Q-GRFT | Ongoing | ||
| Mucosal insert containing TAF and EVG | Pre-clinical | CDC | TAF/EVG | |||||
| Islatravir (EFdA) + Etonogestrel/Ethinyl Estradiol 3D Printed IVR | Microbicides | Pre-clinical | December 2019 | Men | Islatravir (MK-8591) | |||
| Innovative 3D Printed Intravaginal Rings | Microbicides | Pre-clinical | August 2018 | Men | Dapivirine-Levonorgestrel ring | |||
| Amphora/QGriffithsin (QGRFT) fast-dissolving vaginal insert (FDI) | Microbicides | Pre-clinical | May 2021 | NIAID | Q-GRFT | |||
| mAb 2C7 + TDF IVR | Microbicides | Open Label | April 2018 | Men | TDF | Ongoing | ||
| Novel mAb contraceptive + TDF IVR | Microbicides | Pre-clinical | May 2020 | NICHD | TDF | Ongoing | ||
| PREVENT study | Microbicides | I | July 2019 | Rhonda Brand; NIAID; Intrucept Biomedicine LLC | Men, Women | Q-GRFT | ||
| FAME103 | Microbicides | I | August 2020 | NIAID (STUDY19100120) | United States of America | Women | MK-2048 | Ongoing |
| Pop Council PC-6500 Vaginal insert | Microbicides | I | March 2018 | Women | PC-6500 | |||
| MK-8591-016 | PrEP | II | September 2019 | United States of America, Malawi, South Africa, Israel | Men | Islatravir (MK-8591) | Ongoing | |
| CONRAD B17-144 | Microbicides, Multipurpose Prevention Technologies | II | December 2018 | Kenya | Women | TFV/LNG ring, TFV ring | Ongoing | |
| CONRAD A15-140 | Microbicides, PrEP | I | April 2016 | United States of America | Women | TFV ring, TDF/FTC (Truvada) | Completed | |
| CONRAD A15-138 | Microbicides, Multipurpose Prevention Technologies | I | September 2017 | United States of America, Dominican Republic | Men | Levonorgestrel, tenofovir | Completed |
Pages
